Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

President and CEO of Supernus. “In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025 ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

Earlier this month, the FDA approved ONAPGO Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025 ...